Nérès reiterated his proposal to delist around a hundred molecules during the Les Amphis de l’officine conference evening organized Monday, November 25, 2024 by the Federation of Pharmaceutical Unions of France (FSPF). The Nérès association represents 26 pharmaceutical laboratories marketing optional medical prescription drugs, non-prescription medical devices and food supplements. Such a massive delisting would be the responsibility of the National Agency for the Safety of Medicines and Health Products (ANSM).
A doubling of the advice department
“One in two French people have given up seeking treatment over the last 12 months, particularly due to the shortage of general practitioners,” advances Paul-François Cossa, president of Nérès and also head of Opella Healthcare France. Furthermore, nearly 30% of customer flows in pharmacies relate to everyday ailments. This is enough to justify this position of Nérès: “double the number of molecules in the pharmacist’s hand”, explains its president, specifying that the medicines concerned would not be reimbursed however. But they would not necessarily be presented for reimbursement, since the medical prescription is not requested.
The respiratory sphere is the most concerned
According to its estimates, the Nérès association sees significant savings potential for health insurance (nearly 378 million euros in the high range) and complementary insurance (nearly 185 million euros in the high range). Because 1 € spent on a medicinal product from the pharmacy council generates 8 to 9 € in savings for the health system, specifies Paul-François Cossa. The active ingredients which could be delisted in France are already delisted in other European countries: Germany, Spain, Italy, Portugal and also in the United Kingdom. A quarter of the molecules identified concern the respiratory sphere. Specialties in dermatology, others acting on the digestive system or the nervous system could also be delisted as a priority.
Matthieu Vandendriessche
Health
